Sex Hormones in Postmenopausal Women Receiving Low‐Dose Hormone Therapy: The Effect of BMI

Authors:

Abstract
The aim of our study was to evaluate the effect of BMI on the change in circulating sex hormone in postmenopausal women during 6 months of oral continuous combined low‐dose hormone therapy (HT). Fifty postmenopausal women were allocated to receive daily one tablet containing combination of 17β‐estradiol (1 mg)/norethindrone acetate (0.5 mg) for 6 months. Serum levels of follicle‐stimulating hormone (FSH), estradiol, total testosterone, sex hormone‐binding globulin (SHBG), free androgen index (FAI), free estrogen index (FEI), Δ4‐androstendione (Δ4A), and dehydroepiandrosterone sulfate were assessed at baseline and at the end of 6 months. Mean absolute values and percent changes from baseline were compared between lean and overweight women. Mean FSH decreased and mean 17β‐estradiol increased significantly in both groups (FSH lean: 82.3 ± 26.7 decreased to 45.0 ± 17.0 mIU/ml, P = 0.0001; FSH overweight: 85.5 ± 22.1 decreased to 52.3 ± 23.8 mIU/ml, P = 0.003; P between groups = 0.661; E2 lean: 23.24 ± 12.55 increased to 53.62 ± 28.29 pg/ml, P = 0.006; E2 overweight: 24.17 ± 10.88 increased to 68.36 ± 53.99 pg/ml, P = 0.0001; P between groups = 0.619). Lean individuals had statistically significant higher increments of FAI and specifically FEI compared to overweight (FEI lean; 0.14 ± 0.09 increased to 0.29 ± 0.14, P = 0.009; overweight 0.23 ± 0.18 increased to 0.52 ± 0.40, P = 0.126; P between groups = 0.034). Although BMI does not affect total 17β‐estradiol changes, free sex steroid concentrations increase more steeply in lean compared to overweight women receiving oral low‐dose HT.

This publication has 32 references indexed in Scilit: